Ronald C JR Renaud
CIK 1354434 · CEO & President · last filed 2026-06-11
Ronald C JR Renaud is a CEO & President who has filed 55 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for UPB, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$34.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $332.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$332.5K
11
55
-$34.19M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| UPB | Director | — | $6.10 | — | $0 | 3 | 2026-06-11 |
| KLRA | CEO & President | 38,094 | — | — | $0 | 2 | 2026-06-11 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | President & CEO | 244,309 | $44.96 | $10.98M | $2.01M | 4 | 2024-01-23 |
| ATRA | Director | 31,500 | $10.41 | $327.9K | $0 | 3 | 2022-06-27 |
| ImageneBio, Inc. (IKNA) Delisted | Director | — | $17.16 | — | $0 | 2 | 2022-06-13 |
| TBIO | Chief Executive Officer | 0 | $0.00 | $0 | -$36.25M | 9 | 2021-09-14 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 6 | 2019-06-24 |
| AKBA | Director | 5,000 | $0.92 | $4.6K | $59.6K | 6 | 2018-06-15 |
| PTCT | Director | — | $75.14 | — | $0 | 3 | 2017-01-05 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | President & CEO | 89,990 | — | — | $0 | 14 | 2014-08-05 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Financial Officer | 94,027 | — | — | $0 | 2 | 2007-02-16 |
Recent Filings
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | UPB | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | KLRA | Exer (M) | +38,094 | $200.0K | EDGAR |
| 2026-04-20 | KLRA | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-10-15 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-08-05 | — | Disp (D) | −244,309 | $0 | |
| 2024-01-23 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-21 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Exer (M) | +160,452 | $0 | EDGAR |
| 2023-08-07 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Buy (P) | +83,857 | $2.01M | EDGAR |
| 2023-06-14 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | — | $0 | EDGAR |